• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.
【24h】

Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.

机译：根据过敏的严重程度，超急毒液免疫疗法可诱导差异性T细胞活化和调节模式。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Venom immunotherapy (VIT) induces immune tolerance to hymenoptera venom antigens in allergic patients and is therefore a helpful model for studying modulation of allergic immune response. The objectives were to assess the early effects of ultra-rush VIT on T lymphocyte activation and regulatory profile induction, in all subjects combined and according to the four severity grades of the Mueller classification. Materials and Methods Blood samples from 30 vespid-allergic patients were taken before and after the first day of treatment, and before day 15 and day 45 booster injections. IFN-gamma and IL-4 levels were assayed by ELISA, in whole-blood supernatants. IFN-gamma and IL-13-producing T cells, but also natural CD4(+)CD25(+high) regulatory T cells and acquired regulatory T cell proportions were assessed by flow cytometry. Results were analysed in the whole population and compared between patients with I-II or III-IV allergic reactions. Results During VIT, IFN-gamma increased in whole blood when IL-4 decreased. Among T cells, the percentage of CD3(+)IFN-gamma(+) cells increased while IL-13-producing T cells decreased. Proportions of CD4(+)CD25(+high) cells and IL-10-producing T cells increased with VIT. In I-II subjects, IFN-gamma increased gradually, whereas it remained at low levels in III-IV patients. By contrast, IL-4 decrease was more pronounced in III-IV patients. Increase in CD4(+)CD25(+high) T cells occurred early in I-II patients but was delayed in III-IV patients. IL-10-producing T cells increased gradually in both groups but were in a lower proportion in III-IV patients. Conclusion A T helper type 2 (Th2)-to-Th1 switch occurs during ultra-rush VIT, in parallel with natural and acquired regulatory T cell increase. These events occur earlier and at a higher level in less severe subjects, suggesting that VIT tolerance induction is easier to achieve in these patients.
机译：背景技术毒液免疫疗法（VIT）在过敏性患者中诱导对膜翅目毒液抗原的免疫耐受，因此是研究过敏性免疫反应调节的有用模型。目的是根据Mueller分类的四个严重度等级，评估所有受试者中超速VIT对T淋巴细胞活化和调节特征诱导的早期影响。材料和方法在治疗的第一天之前和之后，以及在第15天和第45天加强注射之前，从30例vestent过敏患者中采集血样。通过ELISA在全血上清液中测定IFN-γ和IL-4水平。通过流式细胞术评估产生IFN-γ和IL-13的T细胞，以及天然CD4（+）CD25（+ high）调节性T细胞和获得性调节性T细胞的比例。对整个人群的结果进行了分析，并对患有I-II或III-IV过敏反应的患者进行了比较。结果在VIT期间，IL-4降低时全血中的IFN-γ升高。在T细胞中，CD3（+）IFN-γ（+）细胞的百分比增加，而产生IL-13的T细胞减少。 CD4（+）CD25（+ high）细胞和产生IL-10的T细胞的比例随VIT增加。在I-II受试者中，IFN-γ逐渐增加，而在III-IV患者中则保持较低水平。相比之下，III-IV型患者的IL-4降低更为明显。 I-II患者早期出现CD4（+）CD25（+高）T细胞增加，而III-IV患者则有所延迟。两组中产生IL-10的T细胞逐渐增加，但在III-IV型患者中比例较低。结论在超急诊VIT期间发生T辅助2型（Th2）-Th1转换，同时自然和获得性调节性T细胞增加。这些事件在较不严重的受试者中发生得较早，且水平较高，这表明在这些患者中更容易实现VIT耐受诱导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号